Pacritinib
Brand names: Vonjo · Active ingredient: Pacritinib
In short: VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9/L. This indication is approved under accelerated approval based on spleen volume redu
What is Pacritinib used for?
VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9/L.
This indication is approved under accelerated approval based on spleen volume reduction . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Pacritinib dosage
The recommended dosage of VONJO is 200 mg orally twice daily. VONJO may be taken with or without food.
Swallow capsules whole. Do not open, break, or chew capsules.
Patients who are on treatment with other kinase inhibitors before the initiation of VONJO must taper or discontinue according to the prescribing information for that drug.
Perform a complete blood count (CBC; including white blood cell count differential and platelet count), coagulation testing (prothrombin time, partial thromboplastin time, thrombin time, and international normalized ratio) and a baseline electrocardiogram (ECG), prior to starting VONJO, and monitor as clinically indicated while the patient is on treatment.
If a dose of VONJO is missed, the patient should take the next prescribed dose at its scheduled time. Extra capsules should not be taken to make up for the missed dose.
Discontinue VONJO 7 days prior to elective surgery or invasive procedures because of the risk of hemorrhage and restart only after hemostasis is assured.
Dose modifications for diarrhea, thrombocytopenia, hemorrhage, and prolonged QT interval are described in Table 1, Table 2, Table 3, and Table 4 respectively. See Warning and Precautions (5.1, 5.2, 5.3, and 5.4) for additional risk minimization recommendations.
Dose levels for VONJO are as follows: 200 mg twice daily (initial starting dose), 100 mg twice daily (first dose reduction), 100 mg once daily (second dose reduction). Discontinue VONJO in patients unable to tolerate a dose of 100 mg daily.
Table 1 Dosage Modification for Diarrhea
Toxicity | Management/Action
aIncrease of at least 7 stools per day over baseline, or hospitalization indicated, or severe increase in ostomy output over baseline, or if limiting self-care.
bIncrease of <4 stools per day over baseline or mild increase in ostomy output compared to baseline.
New onset of diarrhea | Initiate anti-diarrheal medications.
Encourage adequate oral hydration.
Grade 3 or 4 a | Hold VONJO until the diarrhea resolves to Grade 1b or lower or baseline. Restart VONJO at the last given dose.
Intensify anti-diarrheal regimen. Provide fluid replacement.
If diarrhea recurs, hold VONJO until the diarrhea resolves to Grade 1b or lower or baseline. Restart VONJO at 50% of the last given dose once the toxicity has resolved.
Concomitant antidiarrheal treatment is required for patients restarting VONJO.
Table 2 Dose Modification for Thrombocytopenia
Worsening Thrombocytopenia | Action
For clinically significant worsening of thrombocytopenia that lasts more than 7 days | Hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved.
If toxicity recurs hold VONJO. Restart VONJO at 50% of the last given dose once the toxicity has resolved. …
How to take Pacritinib — instructions & advice from the label
See FDA approved patient labeling (
Patient Information).
Discuss the following with the patient prior to and during treatment with VONJO:
Current therapy with another kinase inhibitor
Advise patients who are currently taking a kinase inhibitor that they must taper or discontinue their current kinase inhibitor therapy according to the package insert for that drug prior to starting VONJO.
Hemorrhage
Advise patients that VONJO can cause hemorrhage and instruct them to consult their healthcare provider right away if bleeding occurs. Advise patients about how to recognize bleeding and of the urgent need to report any unusual bleeding to their healthcare provider. Patients should urgently seek emergency medical attention for any bleeding that cannot be stopped .
Diarrhea
Advise patients that VONJO can cause diarrhea. Advise patients to stay hydrated while taking VONJO and to inform their healthcare provider if they experience diarrhea. Instruct patients to initiate antidiarrheal medication promptly at the first onset of symptoms (increase in frequency or change in consistency of bowel movements [loosening]) after starting VONJO. …
Warnings & precautions
Do not take this medicine if: VONJO is contraindicated in patients concomitantly using strong CYP3A4 inhibitors or inducers as these medications can significantly alter exposure to pacritinib, which may increase the risk of adverse reactions or impair efficacy [see Warnings and Precautions (5.1, 5.2, 5.3, 5.4), Drug Interactions (7.1), and Clinical Pharmacology (12.3)].
Serious (11%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <100 x 10 9/L. Serious (13%) and fatal (2%) hemorrhages have occurred in VONJO-treated patients with platelet counts <50 x 10 9/L. Grade ≥3 bleeding events (defined as requiring transfusion or invasive intervention) occurred in 15% of patients treated with VONJO compared to 7% of patients treated on the control arm. Due to hemorrhage, VONJO dose-reductions, dose interruptions, or permanent discontinuations occurred in 3%, 3%, and 5% of patients, respectively.
Avoid use of VONJO in patients with active bleeding and hold VONJO 7 days prior to any planned surgical or invasive procedures.
Assess platelet counts periodically, as clinically indicated . Manage hemorrhage using treatment interruption and medical intervention .
VONJO caused diarrhea in approximately 48% of patients compared to 15% of patients treated on the control arm in a clinical trial. The median time to resolution in VONJO-treated patients was 2 weeks. The incidence of reported diarrhea decreased over time with 41% of patients reporting diarrhea in the first 8 weeks of treatment, 15% in Weeks 8 through 16, and 8% in Weeks 16 through 24. Diarrhea resulted in treatment interruption in 3% of VONJO-treated patients. Serious diarrhea adverse reactions occurred in 2% of patients treated with VONJO compared to no such adverse reactions in patients in the control arm. …
Pacritinib side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Hemorrhage
Diarrhea
Thrombocytopenia
Prolonged QT Interval
Major Adverse Cardiac Events
Thrombosis
Secondary Malignancies
Risk of Infection
Symptom Exacerbation Following Interruption or Discontinuation of Treatment
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
PERSIST-2 Trial
The safety of VONJO was evaluated in the randomized, controlled PERSIST-2 trial . In PERSIST-2, key eligibility criteria included adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) MF with splenomegaly and a platelet count ≤100 × 109/L. Prior Janus associated kinase (JAK) inhibitor therapy was permitted. Patients received VONJO at 200 mg twice daily (n=106), 400 mg once daily (n=104), or best available therapy (BAT) (n=98). Forty-seven (44%) of the 106 patients treated with VONJO 200 mg twice daily had a baseline platelet count of <50 × 109/L. The 400 mg once daily dose could not be established to be safe, so further information on this arm is not provided.
In PERSIST-2, among the 106 patients treated with VONJO 200 mg twice daily, the median baseline hemoglobin was 9.7 g/dL and the median drug exposure was 25 weeks. …
Drug interactions
Strong and Moderate CYP3A4 Inhibitors
Pacritinib is predominantly metabolized by CYP3A4. Concomitant use of VONJO with strong and moderate CYP3A4 inhibitors increases pacritinib exposure, which may increase the risk of exposure-related adverse reactions
Co-administration of VONJO with strong CYP3A4 inhibitors is contraindicated .
Monitor patients concomitantly receiving moderate CYP3A4 inhibitors (e.g., fluconazole) for increased adverse reactions and consider VONJO dose modifications based on safety . Concomitant use of VONJO with doses of fluconazole greater than 200 mg once daily has not been studied.
Strong CYP3A4 Inducers
Pacritinib is predominantly metabolized by CYP3A4. Concomitant use of VONJO with strong CYP3A4 inducers decreases pacritinib exposure, which may reduce efficacy of VONJO .
Co-administration of VONJO with strong CYP3A4 inducers is contraindicated .
CYP1A2 Substrates
Pacritinib is an inhibitor of CYP1A2. VONJO increases the plasma concentrations of CYP1A2 substrates ,which may increase the risk of adverse reactions from the CYP1A2 substrate. …
About this medicine
VONJO contains pacritinib citrate, a kinase inhibitor with the chemical name (2E,16E)-11-[2-(pyrrolidin-1-yl)ethoxy]-14,19-dioxa-5,7,27-triazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2,4,6,8,10,12(26),16,21,23-decaene citrate and a molecular weight of 664.7 as citrate salt and 472.59 as a free base. The molecular formula is C28H32N4O3•C6H8O7 and the structural formula is:
VONJO capsule is for oral administration. Each capsule contains 100 mg of pacritinib equivalent to 140.65 mg of pacritinib citrate and the inactive ingredients are microcrystalline cellulose NF, polyethylene glycol 8000 (PEG 8000) NF, and magnesium stearate NF. The gelatin capsule is bovine derived. The capsule shell contains gelatin, titanium dioxide, black iron oxide, erythrosine, red iron oxide, and printing ink containing shellac, propylene glycol, titanium dioxide, sodium hydroxide, and povidone. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 4b5ab444-0e1a-4984-99db-76ad11a298ee. Read the full official label on DailyMed.